Cargando…
Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer
Androgen deprivation therapy (ADT) is a widely used treatment for patients with hormone-sensitive prostate cancer (PCa). However, duration of treatment response varies, and most patients eventually experience disease progression despite treatment. Leuprorelin is a luteinizing hormone-releasing hormo...
Autores principales: | Zou, Yixuan, Tang, Fei, Talbert, Jeffery C., Ng, Chee M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092991/ https://www.ncbi.nlm.nih.gov/pubmed/32208461 http://dx.doi.org/10.1371/journal.pone.0230571 |
Ejemplares similares
-
Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer
por: Tan, Hsern Ern, et al.
Publicado: (2016) -
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
por: Abouelfadel, Zinelabidine, et al.
Publicado: (2008) -
Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
por: Chung, Byung Ha, et al.
Publicado: (2020) -
Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature
por: Benabbad, Imane, et al.
Publicado: (2018) -
A Case of Mental Retardation with Paraphilia Treated with Depot Leuprorelin
por: Park, Woo Sung, et al.
Publicado: (2014)